The case, reported by Lamya Eissa of Alexandria Faculty of Medicine, Esra’a Alyateem of the University of Jordan, and Hassan Magdy Abdelrazek of Mansoura University, describes a completely thrombosed mycotic pseudoaneurysm of the cervical internal carotid artery in a malnourished child. A mycotic aneurysm, despite its name, has nothing to do with fungal infection in most cases; the term refers to an infected, weakened segment of an artery wall that balloons outward under arterial pressure. When such a lesion fills with clot, it loses the flowing blood signal that normally gives it away on imaging, and instead presents as a solid-appearing mass that can be nearly indistinguishable from a collection of pus.

Parapharyngeal abscesses are relatively rare in children but carry serious risk. The parapharyngeal space is a deep compartment of the neck bounded by critical structures, including the carotid sheath, which houses the internal carotid artery, the internal jugular vein, and cranial nerves. Infection in this space can spread along fascial planes toward the mediastinum, and documented vascular complications include arterial narrowing, pseudoaneurysm formation, and ischemic stroke. Prior literature, cited in the report, has described internal carotid artery pseudoaneurysms arising secondary to retropharyngeal and parapharyngeal abscesses, as well as carotid mycotic pseudoaneurysms masquerading as peritonsillar abscesses in pediatric patients.

The danger in this specific scenario is mechanical as much as infectious. If a surgeon incises what appears to be an abscess but is actually an aneurysm, the result can be catastrophic hemorrhage. A pseudoaneurysm is a false aneurysm: blood escapes through a defect in the arterial wall and is contained not by the vessel’s own layers but by surrounding tissue, forming a fragile sac. The classic ultrasound signature of a patent pseudoaneurysm is the so-called to-and-fro waveform, in which blood surges into the sac during systole and back into the artery during diastole. But when the sac is completely thrombosed, that diagnostic flow pattern vanishes, and the lesion becomes a silent impostor.

That is precisely what happened in this child. The initial contrast-enhanced CT was suboptimal, and it suggested an abscess rather than a vascular lesion. Only when the team pursued dedicated, high-quality multimodal imaging did the true nature of the mass emerge. The workup included magnetic resonance imaging with diffusion-weighted imaging and apparent diffusion coefficient mapping, magnetic resonance angiography, and three-dimensional CT angiography. Each modality contributed a different piece of evidence, and together they overturned the working diagnosis before a scalpel ever touched the neck.

The technical logic of this multimodal approach is worth unpacking. Diffusion-weighted imaging is exquisitely sensitive to restricted water diffusion, which is characteristic of pus-filled abscess cavities; on apparent diffusion coefficient maps, abscesses typically show marked hypointensity because the viscous, cellular contents of pus impede the random motion of water molecules. A thrombosed aneurysm, by contrast, contains organized clot whose diffusion characteristics differ from those of an abscess. Magnetic resonance angiography visualizes flowing blood without ionizing radiation and can demonstrate the absence of flow within the lesion as well as the relationship of the mass to the parent internal carotid artery. Three-dimensional CT angiography then provides high-resolution anatomical mapping of the cervical vasculature, delineating the aneurysm’s origin, size, and spatial relationship to the skull base and surrounding structures.

The case also highlights the role of the child’s nutritional status. Malnutrition is known to impair immune function and tissue integrity, and the report’s authors note that the patient was malnourished at presentation. Infected aneurysms in children are rare, and when they occur, they are often secondary to bacteremia, local infection spread, or, as in documented cases, deep neck abscesses eroding into the adjacent carotid artery. The report’s associated subject listings, which include primary herpetic gingivostomatitis and meningitis among related topics, reflect the infectious context in which such vascular complications arise.

What makes this case report valuable to clinicians is not the rarity of the lesion alone but the specificity of the imaging lesson it delivers. Complete thrombosis transforms a mycotic pseudoaneurysm into a mass that can easily be mistaken for an abscess without the right imaging modalities and high-quality imaging, the authors conclude. In practical terms, this means that when a deep neck mass in a child does not behave as expected, when contrast enhancement is suboptimal, or when the anatomical relationship to the carotid sheath is unclear, the workup should escalate to dedicated MRI with diffusion-weighted sequences, MR angiography, and CT angiography rather than proceeding to incision and drainage on the basis of a single imperfect scan.

The stakes of that escalation are enormous. Misdiagnosed and incised, an infected carotid pseudoaneurysm can exsanguinate a patient within minutes, and even when recognized, management is complex, often requiring endovascular or surgical intervention combined with prolonged antimicrobial therapy. Recognized vascular complications of deep neck infections also include internal carotid artery narrowing, as documented in children with retropharyngeal lymphadenitis and abscess, and ischemic stroke secondary to carotid pseudoaneurysm, as reported in the pediatric literature. The parapharyngeal space’s proximity to the carotid sheath means that every deep neck infection carries at least a theoretical vascular risk, and this case demonstrates how that theoretical risk can become a concrete diagnostic trap.

For the broader radiology and pediatric communities, the case reinforces a principle that imaging specialists have long championed: no single modality is definitive, and the diagnosis of a deep neck mass in a child demands correlation across clinical findings, laboratory data, and complementary imaging techniques. The authors’ contribution statement indicates that the work encompassed conceptualization, imaging analysis, study design, and figure preparation, with all authors reviewing and approving the final version. Conducted in accordance with the Declaration of Helsinki and published with informed parental consent, the report adds a well-documented data point to a small but clinically critical literature. As deep neck infections continue to present in emergency departments worldwide, this child’s story stands as a warning that the most familiar diagnosis is not always the correct one, and that the tools to see the difference already exist for those who know to reach for them.

Subject of Research: Pediatric Radiology

Article Title: Thrombosed mycotic aneurysm of the cervical internal carotid artery mimicking a parapharyngeal abscess in a child: a case report of multimodal imaging diagnosis

Article References: Eissa, L., Alyateem, E., & Abdelrazek, H. M. (2026). Thrombosed mycotic aneurysm of the cervical internal carotid artery mimicking a parapharyngeal abscess in a child: a case report of multimodal imaging diagnosis. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06814-9

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06814-9

Keywords: mycotic aneurysm, pseudoaneurysm, internal carotid artery, parapharyngeal abscess, deep neck infection, multimodal imaging, diffusion-weighted MRI, CT angiography, pediatric radiology, thrombosis, case report, diagnostic imaging

Sporadic Creutzfeldt-Jakob disease, or sCJD, accounts for roughly 85 percent of all human prion disorders and strikes approximately one to two people per million each year. It occurs when the normal cellular prion protein, PrP^C, spontaneously refolds into an abnormal, self-propagating shape called PrP^Sc. These misfolded proteins then template the same corruption onto their healthy neighbors, spreading through brain tissue like a molecular contagion. The result is rapidly progressive dementia, myoclonus, cerebellar dysfunction, and eventually akinetic mutism, with no treatment currently able to halt the decline.

What makes this case particularly instructive is how convincingly the early presentation mimicked cerebrovascular disease. The patient, a Han Chinese man with more than a decade of hypertension, developed dizziness, gait instability, and progressive right-sided weakness. Initial brain MRI was interpreted as showing a presumed left parietal subcortical ischemic lesion alongside chronic white matter changes consistent with small vessel disease. Cerebral angiography subsequently confirmed stenosis of the left middle cerebral artery and severe stenosis of the A1 segment of the anterior cerebral artery, seemingly sealing the diagnosis of ischemic stroke secondary to intracranial atherosclerosis.

But the clinical course refused to cooperate. Despite antiplatelet therapy with aspirin, lipid-lowering medication, and circulation-oriented treatment, the patient continued to deteriorate. Rather than stabilizing or following the stepwise pattern typical of recurrent cerebrovascular events, he developed rapidly progressive cognitive impairment, psychiatric disturbances, aphasia, and worsening right hemiparesis. Neurological examination revealed reduced responsiveness, increased upper limb tone, bilateral ankle clonus, and right-sided weakness graded at Medical Research Council level III. This trajectory, the authors note, was fundamentally atypical for a stabilized ischemic stroke.

The diagnostic turning point came from serial neuroimaging. A follow-up MRI performed approximately one month before admission revealed subtle abnormal diffusion-weighted imaging hyperintensity involving the left insular and parietal cortices, initially dismissed as possible ischemic change in the context of pre-existing white matter disease. But a repeat MRI after admission told a very different story: extensive gyriform hyperintensity along the left frontal, parietal, temporal, and insular cortices, with corresponding low signal on apparent diffusion coefficient maps, confirming true diffusion restriction rather than T2 shine-through. This pattern, known as cortical ribboning, does not conform to vascular territories and is characteristic of sCJD.

Cerebrospinal fluid analysis provided the molecular confirmation the imaging had suggested. Total tau protein measured 4,553.50 picograms per milliliter, more than eleven times the laboratory cutoff of less than 399. Phosphorylated tau reached 66.93 picograms per milliliter against a cutoff of less than 50. Most strikingly, the 14-3-3 gamma protein, a marker of rapid neuronal destruction, measured 50,515 arbitrary units per milliliter against a threshold of less than 20,000. Autoimmune encephalitis antibodies were negative, as was metagenomic next-generation sequencing for infectious pathogens. Genetic testing of the PRNP gene in both the patient and his son detected no pathogenic variant, ruling out a hereditary prion disorder.

Applying the 2017 International CJD Surveillance Network criteria, the team classified the case as probable sCJD based on rapidly progressive cognitive impairment, two clinical features including documented cerebellar ataxia and pyramidal signs, characteristic MRI abnormalities showing restricted diffusion in at least two qualifying cortical regions, and positive CSF 14-3-3 within a disease duration under two years. Notably, the electroencephalogram showed only diffuse slowing without the periodic sharp wave complexes often seen in sCJD, and the real-time quaking-induced conversion assay, or RT-QuIC, could not be performed because it was unavailable at the institution despite efforts to arrange external testing.

The absence of RT-QuIC represents an important limitation, the authors acknowledge. Without this highly specific prion-seeding assay or neuropathological confirmation, the diagnosis remains probable rather than definite. Still, the convergence of clinical progression, non-territorial cortical diffusion restriction, and markedly elevated CSF biomarkers within the established diagnostic framework provides a compelling picture. Total tau and phosphorylated tau served as supportive markers of neuronal injury rather than core diagnostic criteria, but their magnitude, particularly total tau exceeding 4,500 picograms per milliliter, strongly supported prion-mediated damage.

The case also illuminates broader patterns in prion disease epidemiology across Asia. Chinese national surveillance has documented more than 2,100 diagnosed prion disease cases, with sCJD representing approximately 88.7 percent and genetic forms about 11.3 percent. An analysis of 1,970 referred cases from 2006 to 2019 across 344 hospitals in 29 provincial-level administrative divisions revealed substantial geographic variation in referral and case recognition, partly attributable to differences in surveillance coverage. These disparities underscore the ongoing challenge of recognizing a rare disease that can present deceptively as something far more common.

For clinicians, the lessons are clear. Coexisting vascular pathology does not exclude neurodegenerative disease. Rapid multidomain neurological decline despite adequate stroke management should prompt diagnostic reassessment rather than continued vascular optimization. Subtle unilateral cortical ribboning may be overlooked or misattributed to ischemic change at an early stage. And CSF biomarker testing, interpreted alongside clinical course, MRI, EEG, and exclusion of alternative diagnoses, can provide the critical evidence needed to redirect care. In this case, timely recognition came too late to alter the outcome, but the diagnostic pathway the authors describe offers a template for catching the next case earlier, before precious weeks are lost pursuing the wrong disease.

Subject of Research: Misdiagnosis of sporadic Creutzfeldt-Jakob disease as ischemic stroke and biomarker-based diagnostic clarification

Article Title: Case Report: Sporadic Creutzfeldt–Jakob disease initially misdiagnosed as ischemic stroke: a diagnostic challenge and biomarker-based clarification

Article References: Hao, W., Zhou, X., Wang, M., Yang, W., & Cheng, T. (2026). Case Report: Sporadic Creutzfeldt–Jakob disease initially misdiagnosed as ischemic stroke: a diagnostic challenge and biomarker-based clarification. Frontiers in Cellular Neuroscience, 20, Article 1938627. https://doi.org/10.3389/fncel.2026.1938627

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1938627

Keywords: Creutzfeldt-Jakob disease, prion disease, ischemic stroke, cortical ribboning, CSF biomarkers, 14-3-3 protein, tau protein, diffusion-weighted MRI, rapidly progressive dementia, misdiagnosis, RT-QuIC, neurodegeneration

Rapidly progressive dementia, defined by cognitive decline that unfolds over weeks to months rather than years, presents neurologists with one of the most urgent diagnostic challenges in medicine. The two leading causes are prion diseases, most commonly sporadic Creutzfeldt-Jakob disease, and rapidly progressive forms of Alzheimer disease. In typical presentations, the two can be separated with reasonable confidence: prion disease usually announces itself on magnetic resonance imaging with characteristic diffusion-weighted abnormalities, and cerebrospinal fluid tests for prion seeding activity can confirm suspicion. But as the new research demonstrates, a subset of patients slips through these diagnostic nets entirely, presenting with clinical pictures that faithfully reproduce the amnestic syndromes of Alzheimer disease.

The Mayo Clinic team, led by Anas Elgenidi and Gregory S. Day, examined a prospective cohort of 204 patients with rapidly progressive dementia evaluated between February 2020 and June 2026. Among these, five patients, or 2.5 percent, had been diagnosed with clinically probable Alzheimer disease but were ultimately determined to have prion disease. That figure may seem small, but its significance lies in what it reveals about the limits of current diagnostic algorithms. These were not obscure cases buried in ambiguity; they were patients who met accepted criteria for Alzheimer disease and behaved, at least initially, exactly as that diagnosis predicted.

To understand how widespread this phenomenon is, the researchers turned to a systematic review of MEDLINE and Embase, unearthing ten additional published cases. Together with the Mayo cohort, the analysis encompassed fifteen patients with a median age at onset of 59 years, roughly two-thirds of whom were male. The clinical phenotypes these patients displayed mapped remarkably well onto recognized Alzheimer disease variants: just over half presented with an amnestic syndrome dominated by memory loss, about a quarter with a dysexecutive pattern affecting planning and organization, and smaller proportions with primary progressive aphasia, a language-led deterioration, or posterior cortical atrophy, which disrupts visual processing and spatial abilities. In other words, these prion cases were not merely Alzheimer-like in a vague sense; they reproduced specific, named Alzheimer phenotypes with precision.

The technical details of the diagnostic workup reveal where the traditional tools faltered. Diffusion-weighted magnetic resonance imaging, widely regarded as a cornerstone of prion disease diagnosis, was absent in all of the Mayo Clinic cases. In the published cases, the characteristic imaging abnormalities were either absent or equivocal in two patients and, perhaps more troublingly, overlooked in eight. This pattern of missed radiological findings echoes earlier literature showing that MRI changes in Creutzfeldt-Jakob disease are frequently misread or underappreciated, particularly early in the disease course when cortical and basal ganglia changes may be subtle or confined to regions that are not scrutinized routinely.

Cerebrospinal fluid biomarkers added another layer of complexity. In six of nine tested patients, the CSF profile was actually consistent with Alzheimer disease, meaning the amyloid and tau signature that clinicians rely upon to confirm the diagnosis pointed in the wrong direction. Elevated total tau levels, however, emerged as a recurring signal: eleven of thirteen patients showed raised total tau, and in five of nine patients the ratio of total tau to phosphorylated tau 181 was disproportionately elevated. This distinction matters because total tau reflects neuronal injury in a relatively nonspecific fashion, whereas phosphorylated tau is more closely tied to Alzheimer-type pathology. When total tau climbs far out of proportion to phosphorylated tau, the brain is being injured faster and more destructively than Alzheimer disease alone typically explains, and prion disease should enter the differential.

The most definitive diagnostic tool in the study was the real-time quaking-induced conversion assay, or RT-QuIC, a laboratory technique that exploits the prion protein’s infectious misfolding behavior. In the assay, normal recombinant prion protein is exposed to a patient’s cerebrospinal fluid and agitated; if misfolded prions are present, they template the conversion of the normal protein into amyloid fibrils that can be detected with a fluorescent dye, providing a sensitive and specific readout of prion seeding activity. RT-QuIC was positive in the cerebrospinal fluid of nine of twelve patients tested. Across the full cohort, prion disease was ultimately confirmed by neuropathological examination in seven cases, by genetic testing in two, and by RT-QuIC in six, illustrating that no single modality sufficed in every patient.

The median interval between the initial Alzheimer diagnosis and the consideration of prion disease was two months, a delay that, while seemingly brief, is meaningful in a disease measured in months. The stakes are considerable. Prion diseases are uniformly fatal, typically causing death within a year of onset, and there is no established cure, although the field is stirring: an early-phase clinical trial of intrathecally administered prion protein siRNA, a gene-silencing therapy delivered into the spinal fluid, is now enrolling symptomatic patients. Accurate diagnosis also matters for infection control, since prions resist conventional sterilization and demand specialized decontamination protocols in surgical settings, and for genetic counseling, since a proportion of prion disease cases arise from mutations in the prion protein gene with implications for family members.

The timing of this research is particularly consequential given the transformation of Alzheimer therapeutics. With disease-modifying monoclonal antibodies such as lecanemab and donanemab now approved and increasingly deployed, the pressure to confirm an Alzheimer diagnosis early and confidently has never been greater. Blood-based biomarkers are being promoted as accessible confirmatory tests, and CSF profiles are routinely used to anchor clinical decisions. Yet this study demonstrates that a positive Alzheimer biomarker signature does not exclude prion disease, and that patients with rapidly progressive courses deserve scrutiny that goes beyond a single biomarker panel. A patient whose dementia gallops forward while their biomarkers say Alzheimer may, in rare instances, be harboring a prion.

The authors’ central recommendation is pragmatic and easily actionable: disproportionate elevations in cerebrospinal fluid total tau, or an abnormally high ratio of total tau to phosphorylated tau 181, should prompt clinicians to consider prion disease and pursue RT-QuIC testing. Combined with careful re-review of diffusion-weighted MRI, this biomarker-driven vigilance offers a path to catching these mimics earlier. For the vast majority of patients with rapidly progressive dementia, the diagnosis will not be prion disease, and Alzheimer disease itself remains a common and legitimate explanation for swift decline. But for the roughly one in forty patients in this cohort whose illness wore Alzheimer’s mask, the difference between a routine diagnosis and a searching second look was the difference between two entirely different diseases, and the study stands as a reminder that in neurology, the most convincing diagnosis sometimes deserves to be tested against its own biomarkers.

Subject of Research: Prion disease presenting as rapidly progressive Alzheimer disease, diagnosed through CSF tau biomarkers and RT-QuIC assays

Article Title: Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review

Article References: Elgenidi, A., Shir, D., Piura, Y. D., Sokol, L. L., Duara, R., Lachner, C., & Day, G. S. (2026). Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review. Journal of Neurology, 273(10), Article 565. https://doi.org/10.1007/s00415-026-14087-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14087-3

Keywords: prion disease, Creutzfeldt-Jakob disease, Alzheimer disease, rapidly progressive dementia, RT-QuIC, cerebrospinal fluid biomarkers, total tau, phosphorylated tau, diffusion-weighted MRI, differential diagnosis, neurodegeneration, Mayo Clinic

The logic behind the conventional approach is simple: because glioblastoma cells creep microscopically into surrounding tissue, the radiation field must be larger than the visible tumor. But histopathologic and preclinical studies have long shown that glioblastoma does not spread isotropically. Instead, it migrates preferentially along large white matter pathways, the bundled fiber tracts that connect distant brain regions. The tumor behaves less like an inflating balloon and more like water flowing through a network of pipes, racing along highways of myelinated axons while slowing at natural barriers. Yet this biological reality has never been systematically built into radiotherapy planning, until now.

A team led by Michael Wahl of the University of California, San Francisco, together with colleagues across UCSF’s radiation oncology, neurology, radiology and neurosurgery departments, has now translated that insight into a clinically workable technique. Their method uses diffusion-weighted MRI, which measures how freely water molecules diffuse through tissue. In organized white matter, water diffuses preferentially along the axis of the fiber bundles, a phenomenon called anisotropy. Tractography algorithms exploit this signal to reconstruct the trajectories of white matter fiber pathways throughout the entire brain, effectively drawing a wiring diagram of each individual patient.

The technical pipeline behind the study is a careful exercise in modern imaging science. Thirteen glioblastoma patients underwent 55-direction high angular resolution diffusion imaging on a 3 Tesla scanner as part of their postoperative radiation planning MRI, an acquisition of only seven to eight minutes. After correcting the data for head motion and eddy-current distortion using the FMRIB Software Library, the researchers fit both a tensor model and a higher-order Q-ball model with the open-source DIPY package, the latter to accurately resolve regions where fiber bundles cross. White matter, defined as voxels with fractional anisotropy above 0.15, was seeded densely, and a residual-bootstrap tractography approach estimated fiber orientations probabilistically, terminating streams when anisotropy fell below threshold or fibers bent more than sixty degrees.

Here is where the innovation crystallizes. The team selected all tractography streamlines passing within five millimeters of the visible tumor, the gross tumor volume delineated from the surgical cavity, contrast-enhancing regions and mass-like T2-FLAIR abnormality. From this subset they generated a scalar map in which every voxel stores its minimum white matter path length to the tumor, the shortest distance along actual fiber tracts rather than straight-line distance. The result is an anatomically informed expansion: the target flows along the superior cingulum bundle in one patient, crosses to the opposite hemisphere through the splenium of the corpus callosum in another, and in a third tracks along the inferior longitudinal fasciculus, precisely the routes along which those tumors later spread. In every one of the thirteen cases, the resulting contours respected natural anatomic boundaries that the standard circular expansion ignored.

The payoff appears in the numbers. When the researchers generated clinical target volumes by thresholding the path length maps at two centimeters and compared them, within the same patient, to the guideline-conformant two-centimeter isotropic expansion, the tractography-based volumes were a median of 67 cubic centimeters smaller, roughly a nineteen percent reduction, a difference that reached statistical significance. The one-centimeter variant shrank targets even more dramatically, by 39 percent on average, though at the cost of missing several recurrences captured by the standard volume. At three centimeters, the tractography volume converged with the standard one, as expected. These volumes were imported directly into the RayStation treatment planning system, demonstrating that the approach is compatible with routine clinical workflows rather than confined to research software.

The more consequential question is whether these sculpted volumes actually contain the places where tumors come back. To answer it, the team performed a patterns-of-failure analysis, rigidly registering each patient’s recurrence MRI to the planning scans and classifying recurrences as central, in-field, marginal or distant relative to each target definition. The median time to recurrence was twelve months. Ten of the thirteen recurrence volumes fell entirely within the conventional isotropic target, but twelve of thirteen were encompassed by the two-centimeter tractography-based volume, all while that volume was substantially smaller. In two cases, the recurrent tumor was clearly infiltrating along a major white matter tract inside the tractography target but outside the standard one, exactly the failure mode the technique was designed to prevent.

The clinical context makes these findings timely. Historical teaching held that ninety percent of glioblastoma recurrences occur within a two-centimeter margin of the original tumor, a figure that discouraged tinkering with target delineation. But more recent studies of patients treated with concurrent temozolomide, particularly those whose tumors carry methylation of the MGMT promoter and are therefore more drug-sensitive, have shown marginal or distant recurrence rates approaching forty percent, suggesting that current volumes may undertreat pockets of microscopic disease in some patients. At the same time, generous circular expansions irradiate substantial volumes of healthy brain, raising the specter of radiation necrosis and long-term neurocognitive decline. An approach that could simultaneously tighten targets and extend them along true routes of invasion promises the rarest of things in oncology: better coverage with less collateral damage.

The researchers are appropriately measured about what their study can and cannot claim. Thirteen patients cannot prove a statistical reduction in marginal or distant recurrences, and the pattern-of-failure analysis was observational and hypothesis-generating. Even demonstrating that a recurrence fell within a tractography target does not prove that treating that volume would have prevented it, since most patients still recur within the high-dose region regardless of technique. The small sample also prevented confident optimization of the tracking parameters and path length thresholds, and no dosimetric analysis of organ-at-risk sparing has yet been performed. Validation in a larger prospective cohort, with formal assessment of normal brain sparing through dose-volume statistics, is the clearly stated next step.

Still, as a proof of concept, the study is striking in its feasibility and simplicity. The imaging sequence adds only minutes to a standard planning MRI, the analysis relies on open-source tools, and the output drops directly into commercial treatment planning software. What the UCSF team has shown is that the brain’s own anatomy can be enlisted as a map of where an incurable tumor is likely to travel next, replacing a geometric convention inherited from decades-old CT studies with a personalized, biologically grounded contour. If larger trials confirm that two centimeters along a nerve fiber tract is worth more than two centimeters in a straight line, the humble circle that has defined glioblastoma radiotherapy for a generation may finally be retired, and one of medicine’s grimmest diagnoses may gain a small but meaningful edge.

Subject of Research: Tractography-based clinical target volume delineation for glioblastoma radiotherapy planning

Article Title: White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma

Article References: Wahl, M., Chapman, C. H., Morin, O., Jordan, K., Henry, R. G., Chang, S. M., Villanueva-Meyer, J. E., Mukherjee, P., Theodosopoulos, P., McDermott, M. W., Berger, M. S., Sneed, P., Braunstein, S. E., & Lupo, J. M. (2026). White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma. Journal of Neuro-Oncology, 179(3), Article 102. https://doi.org/10.1007/s11060-026-05789-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05789-9

Keywords: glioblastoma, diffusion-weighted MRI, tractography, radiotherapy planning, white matter, clinical target volume, patterns of failure, tumor recurrence, neuro-oncology, UCSF, temozolomide, medical imaging

The technique rests on diffusion-weighted MRI, which sensitizes the MR signal to the random Brownian motion of water molecules. In a typical acquisition, the signal is measured along many diffusion-encoding directions, and a model is fitted to describe how the apparent diffusion coefficient varies with direction. In most brain tissue, diffusion is restricted and anisotropic, meaning water moves more easily along axonal bundles than across them. Free water imaging extends the standard diffusion tensor model by adding an isotropic compartment: a fraction of the voxel’s water is assumed to diffuse freely and equally in all directions, unconstrained by tissue microstructure. The estimated volume fraction of this compartment, often called the free water fraction, is the quantity that studies have linked to Parkinson’s disease.

What the commentary emphasizes is that this seemingly single number is, in practice, the product of a long chain of decisions. Every stage of the pipeline matters: the strength and number of diffusion-encoding gradients, the number of directions acquired, the echo time and voxel size, the correction for head motion and eddy currents, the approach to removing non-brain tissue, the handling of signal dropout, the fitting algorithm used to estimate the free water fraction, and the way regions of interest are defined in the midbrain. Each of these choices can shift the estimated values, and because different studies make different choices, their results are not always directly comparable.

This matters acutely in Parkinson’s disease research because the effect sizes involved are modest. The changes in free water fraction reported between people with Parkinson’s disease and healthy controls are typically small in absolute terms, often on the order of a few tenths of a percent to a few percent of the signal fraction. When the biological signal is that subtle, even small methodological differences can rival or exceed the effect being sought. A pipeline that smooths data aggressively, or that defines the substantia nigra generously, may report group differences where a more conservative pipeline finds none. Conversely, an underpowered or noisy acquisition may obscure real biology. The commentary’s central claim is that free water imaging findings in Parkinson’s disease should therefore be read as conditional statements, valid for a particular acquisition, preprocessing stream, and region-of-interest strategy, rather than as universal truths about the diseased brain.

The stakes are high because free water imaging has been proposed as a candidate imaging biomarker for disease progression and for use in clinical trials. Several longitudinal studies have suggested that free water fraction in the substantia nigra increases over time in people with Parkinson’s disease, raising hopes that the measure could serve as a sensitive endpoint for disease-modifying therapies. If those hopes are to be realized, the field needs to know how much of the measured change reflects biology and how much reflects the measurement apparatus. A biomarker that drifts with scanner software updates, or that responds more strongly to a change in preprocessing than to a change in the disease, cannot support the weight of a multi-center trial.

The commentary also addresses a conceptual trap: the tendency to interpret an elevated free water fraction as a direct, one-to-one readout of neuroinflammation. The biological rationale is plausible, because inflammatory processes such as astrocytic activation and microglial responses can expand the extracellular space and increase the mobility of water. But elevated free water is not specific to inflammation. Edema, enlarged perivascular spaces, tissue atrophy with partial volume effects from cerebrospinal fluid, and even residual artifacts from motion or susceptibility gradients can all inflate the estimate. Treating free water fraction as a binary indicator of an active inflammatory process, present or absent, oversimplifies what is in fact a composite measurement influenced by multiple tissue properties and multiple sources of error.

Partial volume contamination deserves particular attention in the midbrain, where the structures of interest are small and intimately surrounded by cerebrospinal fluid spaces. The substantia nigra lies adjacent to the interpeduncular cistern, and even with careful region-of-interest placement, signal from free cerebrospinal fluid can leak into the measured voxels, especially at the resolutions commonly used in research scanning. Some pipelines attempt to correct for this, while others rely on conservative masking. The commentary suggests that differences in how this problem is handled may explain a substantial portion of the variability in the literature, with some studies reporting robust group differences and others reporting null results for ostensibly similar comparisons.

None of this, the authors are careful to note, amounts to a dismissal of free water imaging. On the contrary, the technique remains one of the most promising MRI-based approaches to the nigral pathology that defines Parkinson’s disease, precisely because it targets a biologically meaningful property of tissue rather than a gross structural change that appears only late in the disease course. The argument is for methodological transparency and rigor: studies should report their acquisition parameters and preprocessing steps in full, share their analysis code where possible, and validate their pipelines against phantom data or across independent datasets. Harmonization efforts across scanning sites, and sensitivity analyses that show how results change under alternative processing choices, would allow the field to distinguish findings that are robust from those that are artifacts of a particular workflow.

For clinicians and trial designers, the practical message is one of calibrated expectations. Free water imaging is not yet a diagnostic test, and a single elevated value in an individual patient should not be read as a verdict on their disease state. The technique’s near-term value lies in group-level comparisons and longitudinal tracking within carefully controlled studies, where its sensitivity to change can be exploited while its methodological dependencies are held constant. As the field moves toward standardization, the commentary argues, the goal should be pipelines whose outputs are stable across sites and scanners, so that the biological signal of neurodegeneration can finally be separated from the technical noise of measurement. In free water imaging, the method is not a mere technicality; it is part of the result itself, and recognizing that is the first step toward turning an intriguing research measurement into a dependable clinical tool.

Subject of Research: The influence of image processing methodology on free water imaging measurements in Parkinson's disease

Article Title: The method matters: free water imaging in Parkinson’s disease is not a binary verdict

Article References: Martinez-Nunez, A. E., Barmpoutis, A., Okun, M. S., & Vaillancourt, D. (2026). The method matters: free water imaging in Parkinson’s disease is not a binary verdict. npj Parkinson's Disease, 12(1), Article 217. https://doi.org/10.1038/s41531-026-01492-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01492-8

Keywords: Parkinson's disease, free water imaging, diffusion MRI, neuroinflammation, biomarkers, image processing, substantia nigra, magnetic resonance imaging, neurodegeneration, methodology, method, matters